Hemodynamics and survival of patients with portopulmonary hypertension

Liver Transplantation

Volumn 11, Issue 9, 2005, Pages 1107-1111

  Kawut, Steven M ^a,b,d   Taichman, Darren B ^c   Ahya, Vivek N ^c   Kaplan, Sandra ^c   Archer Chicko, Christine L ^c   Kimmel, Stephen E ^c   Palevsky, Harold I ^c  

^a Columbia University ^*  (United States)

^b University of Pennsylvania School of Medicine ^*  (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Pulmonary Division   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; PROSTACYCLIN; SPIRONOLACTONE; WARFARIN;

ADULT; ARTERY CATHETERIZATION; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART INDEX; HEMODYNAMICS; HIGH RISK POPULATION; HUMAN; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; MALE; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADULT; COHORT STUDIES; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 25144515518     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20459     Document Type: Article

References (22)

1. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(Suppl S):S5-S12.
2. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-528.
3. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology 2003;37:401-409.
4. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B,, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989;80:1198-1206.
5. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302.
6. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30:641-648.
7. Swanson KL, McGoon MD, Krowka MJ. Survival in patients with portopulmonary hypertension [abstract]. Am J Respir Crit Care Med 2003;167:A693.
8. Krowka MJ, Mandell MS, Ramsay MA, Kawut SM, Fallon MB, Manzarbeitia C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant database. Liver Transpl 2004;10:174-182.
9. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
10. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-hepatic vascular disorders. Eur Respir J 2004;24:861-880.
11. Groves BM, Brundage BH, Elliott CG, Koerner SK, Fisher JD, Peter RH, et al. Pulmonary hypertension associated with hepatic cirrhosis. In: Fishman AP, ed. The pulmonary circulation: normal and abnormal. Philadelphia, PA: University of Pennsylvania Press; 1990:359-369.
12. Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
13. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(Suppl S):40S-47S.
14. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;34:187-220.
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81: 515-526.
16. Rothman KJ, Greenland S. Accuracy considerations in study design. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. Philadelphia, PA: Lippincott Williams and Wilkins; 1998: 135-145.
17. Fishman AP. Dietary pulmonary hypertension. Circ Res 1974; 35:657-660.
18. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, Rubin LJ. Distinctive clinical features of portopulmonary hypertension. Chest 1997;112:980-986.
19. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001; 89:273-293.
20. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: Direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75-80.
21. Kawut SM, Horn EM, Berekashvili KK, Garofano RP, Goldsmith RL, Widlitz AC, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95:199-203.
22. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461-1468.